WHO ICTRP trial
ED50 and ED95 of epidural ropivacaine combined with sufentanil for…
ChiCTR2400091541 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400091541 |
|---|---|
| Public title | ED50 and ED95 of epidural ropivacaine combined with sufentanil for intraoperative analgesia in high-intensity focused ultrasound treatment of adenomyosis |
| Scientific title | The perioperative efficacy of epidural ropivacaine in high-intensity focused ultrasound treatment of adenomyosis |
| Primary sponsor | Suining Central Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | adenomyosis |
| Interventions | Experimental group:The initial concentration of ropivacaine is set at 0.065%. If analgesia is ineffective, the concentration is increased by 0.005%. If analgesia is effective, the concentration is decreased by 0.005% |
| Registration date | Oct 30, 2024 |
| Target size | Experimental group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: